149 related articles for article (PubMed ID: 37644453)
1. First experiences using transurethral ultrasound ablation (TULSA) as a promising focal approach to treat localized prostate cancer: a monocentric study.
Peters I; Hensen B; Glandorf J; Gutberlet M; Dohna M; Struckmann S; Kuczyk MA; Wacker F; Hellms S
BMC Urol; 2023 Aug; 23(1):142. PubMed ID: 37644453
[TBL] [Abstract][Full Text] [Related]
2. Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA).
Lumiani A; Samun D; Sroka R; Muschter R
Urol Oncol; 2021 Dec; 39(12):830.e9-830.e16. PubMed ID: 34144892
[TBL] [Abstract][Full Text] [Related]
3. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
Chin JL; Billia M; Relle J; Roethke MC; Popeneciu IV; Kuru TH; Hatiboglu G; Mueller-Wolf MB; Motsch J; Romagnoli C; Kassam Z; Harle CC; Hafron J; Nandalur KR; Chronik BA; Burtnyk M; Schlemmer HP; Pahernik S
Eur Urol; 2016 Sep; 70(3):447-55. PubMed ID: 26777228
[TBL] [Abstract][Full Text] [Related]
4. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer: A Systematic Review.
Dora C; Clarke GM; Frey G; Sella D
J Endourol; 2022 Jun; 36(6):841-854. PubMed ID: 35029127
[No Abstract] [Full Text] [Related]
5. Salvage Magnetic Resonance Imaging-guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer: 12-Month Functional and Oncological Results.
Anttinen M; Mäkelä P; Viitala A; Nurminen P; Suomi V; Sainio T; Saunavaara J; Taimen P; Sequeiros RB; Boström PJ
Eur Urol Open Sci; 2020 Dec; 22():79-87. PubMed ID: 34337481
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study.
Nair SM; Hatiboglu G; Relle J; Hetou K; Hafron J; Harle C; Kassam Z; Staruch R; Burtnyk M; Bonekamp D; Schlemmer HP; Roethke MC; Mueller-Wolf M; Pahernik S; Chin JL
BJU Int; 2021 May; 127(5):544-552. PubMed ID: 33037765
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic hyperplasia: 12-month clinical outcomes of a phase I study.
Viitala A; Anttinen M; Wright C; Virtanen I; Mäkelä P; Hovinen T; Sainio T; Saunavaara J; Taimen P; Blanco Sequeiros R; Boström PJ
BJU Int; 2022 Feb; 129(2):208-216. PubMed ID: 34161649
[TBL] [Abstract][Full Text] [Related]
8. Relief of Lower Urinary Tract Symptoms After MRI-Guided Transurethral Ultrasound Ablation for Localized Prostate Cancer: Subgroup Analyses in Patients with Concurrent Cancer and Benign Prostatic Hyperplasia.
Elterman D; Li W; Hatiboglu G; Relle J; Zorn KC; Bhojani N; Chin J
J Endourol; 2021 Apr; 35(4):497-505. PubMed ID: 32935575
[No Abstract] [Full Text] [Related]
9. Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate cancer: single-center evaluation of 6-month treatment safety and functional outcomes of intensified treatment parameters.
Hatiboglu G; Popeneciu V; Bonekamp D; Burtnyk M; Staruch R; Pahernik S; Tosev G; Radtke JP; Motsch J; Schlemmer HP; Hohenfellner M; Nyarangi-Dix JN
World J Urol; 2020 Feb; 38(2):343-350. PubMed ID: 31062122
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer.
Anttinen M; Mäkelä P; Suomi V; Kiviniemi A; Saunavaara J; Sainio T; Horte A; Eklund L; Taimen P; Sequeiros RB; Boström PJ
Scand J Urol; 2019 Oct; 53(5):295-302. PubMed ID: 31556779
[No Abstract] [Full Text] [Related]
11. Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate.
Bonekamp D; Wolf MB; Roethke MC; Pahernik S; Hadaschik BA; Hatiboglu G; Kuru TH; Popeneciu IV; Chin JL; Billia M; Relle J; Hafron J; Nandalur KR; Staruch RM; Burtnyk M; Hohenfellner M; Schlemmer HP
Eur Radiol; 2019 Jan; 29(1):299-308. PubMed ID: 29943185
[TBL] [Abstract][Full Text] [Related]
12. Medium-term Oncological Efficacy and Patient-reported Outcomes After Focal High-intensity Focused Ultrasound: The FOXPRO Trial.
Westhoff N; Ernst R; Kowalewski KF; Derigs F; Neuberger M; Nörenberg D; Popovic ZV; Ritter M; Stephan Michel M; von Hardenberg J
Eur Urol Focus; 2023 Mar; 9(2):283-290. PubMed ID: 36344395
[TBL] [Abstract][Full Text] [Related]
13. Salvage open radical prostatectomy for recurrent prostate cancer following MRI-guided transurethral ultrasound ablation (TULSA) of the prostate: feasibility and efficacy.
Nair SM; Stern N; Dewar M; Siddiqui K; Smith E; Gomez JA; Moussa M; Chin JL
Scand J Urol; 2020 Jun; 54(3):215-219. PubMed ID: 32308085
[No Abstract] [Full Text] [Related]
14. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.
Ahmed HU; Hindley RG; Dickinson L; Freeman A; Kirkham AP; Sahu M; Scott R; Allen C; Van der Meulen J; Emberton M
Lancet Oncol; 2012 Jun; 13(6):622-32. PubMed ID: 22512844
[TBL] [Abstract][Full Text] [Related]
15. Acute and subacute prostate MRI findings after MRI-guided transurethral ultrasound ablation of prostate cancer.
Mäkelä P; Anttinen M; Suomi V; Steiner A; Saunavaara J; Sainio T; Horte A; Taimen P; Boström P; Blanco Sequeiros R
Acta Radiol; 2021 Dec; 62(12):1687-1695. PubMed ID: 33251811
[TBL] [Abstract][Full Text] [Related]
16. Fiducial markers and their impact on ablation outcome for patients treated with MR-guided transurethral ablation (TULSA): a retrospective technical analysis.
Wright C; Mäkelä P; Anttinen M; Sainio T; Boström PJ; Blanco Sequeiros R
Int J Hyperthermia; 2021; 38(1):1677-1684. PubMed ID: 34927517
[TBL] [Abstract][Full Text] [Related]
17. [HIFU therapy of localized prostate cancer using image-guided robotic HIFU Focal One].
Govorov AV; Vasilyev AO; Alaverdyan AI; Kolontarev KB; Pushkar DY
Urologiia; 2023 May; (2):83-89. PubMed ID: 37401710
[TBL] [Abstract][Full Text] [Related]
18. Focal Therapy for Prostate Cancer with In-Bore MR-guided Focused Ultrasound: Two-Year Follow-up of a Phase I Trial-Complications and Functional Outcomes.
Tay KJ; Cheng CWS; Lau WKO; Khoo J; Thng CH; Kwek JW
Radiology; 2017 Nov; 285(2):620-628. PubMed ID: 28654336
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of post-ablation mpMRI as a predictor of residual prostate cancer after focal high intensity focused ultrasound (HIFU) ablation.
Khandwala YS; Morisetty S; Ghanouni P; Fan RE; Soerensen SJC; Rusu M; Sonn GA
Urol Oncol; 2022 Nov; 40(11):489.e9-489.e17. PubMed ID: 36058811
[TBL] [Abstract][Full Text] [Related]
20. Focal cryosurgical ablation of the prostate: a single institute's perspective.
Hale Z; Miyake M; Palacios DA; Rosser CJ
BMC Urol; 2013 Jan; 13():2. PubMed ID: 23311921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
